CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-04-16): Gilead drug effective against liver disease: study

Drug & Device Development

Gilead drug effective against liver disease: study

Last Updated: 2010-04-16 18:37:14 -0400 (Reuters Health)

LOS ANGELES (Reuters) - Gilead Sciences Inc's experimental drug, GS-9450, was shown in a mid-stage trial to improve markers of liver damage in patients with non-alcoholic steatohepatitis.

Researchers said the phase II trial, involving 124 patients, showed treatment with the drug reduced levels of alanine (ALT) and aspartate aminotransferases (AST)

The results were presented on Friday in Vienna at the International Liver Congress.

GS-9450 is a caspase inhibitor designed to block proteins that initiate apoptosis in damaged cells.

Gilead said the drug is a potential new treatment option for patients with non-alcoholic steatohepatitis.

Further studies are needed to evaluate the drug's efficacy and safety in larger patient populations.

The trial showed that, after four weeks, 35% of patients treated with the highest dose of GS-9450 achieved ALT levels within the normal range. Forty-eight percent achieved normal levels of AST. Placebo treatment showed no meaningful change for either enzyme.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.